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Case Report
Local thrombolytic treatment of Cerebral Venous Thrombosis in three paediatric
patients
Mohammad Wasay1, Rohit Bakshi2, Alper Dai3, Steve Roach4
Department of Neurology, The Aga Khan University, Karachi1, Harvard University, Brigham and women Hospital, Boston2, Gaziantep University,
Gaziantep, Turkey3, Ohio State University School of Medicine4, Columbus, OH.

Abstract
There is increasing evidence that local thrombolysis
can be used with relative safety and efficacy in adults with
superior sagittal sinus thrombosis (SSST). However, little data
is available on the use of local thrombolysis in children with
SSST. We report three patients who received local thrombolysis for dural sinus thrombosis. Two patients received urokinase
and one patient received urokinase followed by local TPA infusion. Recanalization was achieved in two patients.

Introduction
Superior sagittal sinus thrombosis (SST) is uncommon
in children. Several treatment protocols have been used for
treatment of paediatric SST, including hydration, antibiotics,
steroids, diuretics, osmotic agents, antiplatelet therapy, systemic
anticoagulation and systemic and local thrombolysis.1-3 The use
of TPA in paediatric SST has not been reported but there are a
few reported cases of urokinase thrombolysis in these patients.
We report three patients with dural sinus thrombosis. Two
patients received locally administered urokinase and the other
was treated with local TPA infusion. One of these patients was
referred to briefly in a recent large series.4

Case Report
Patient 1: A four-year-old boy with nephrotic syndrome presented with headache and irritability. General physical and
neurologic examinations were unremarkable except for
lethargy. Head CT showed hyperdensity of the superior sagittal sinus (SSS) and straight sinus (StS). MRI with MR venography (MRV) showed thrombosis of the SSS and the straight
sinus (StS). Catheter angiography confirmed thrombosis of
SSS, StS and left transverse sinus (TS). An angiographic
catheter was placed into internal jugular vein via transfemoral
catheterization. A Tracker -18 microcatheter (Target
Therapeutics, CA) was advanced through angiographic
catheter into the superior sagittal sinus. The patient received
a bolus of urokinase (50,000 units) into SSS. The catheter was
retained in the SSS and urokinase was infused continuously
at 5000 units per hour. A repeat angiogram 20 hours later
showed patency of SSS. There were no complications. Patient
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was subsequently started on oral warfarin. He was discharged
with a normal neurologic status.
Patient 2: A 12-year-old girl with systemic lupus erythematosus and lupus nephritis presented with headache and difficulty
with ambulation. Neurologic examination showed papilloedema and gait ataxia. Her laboratory evaluation was unremarkable except for an elevated prothrombin time (23.8 seconds)
and positive antiphospholipid antibodies. Brain MRI/MRV
showed small bilateral subdural haematomas and thrombosis
of superior sagittal sinus, straight sinus and right transverse
sinus. Catheter angiography confirmed the MRV findings.
Intravenous heparin was started but there was no neurologic
improvement after 24 hours. A 5F angiographic catheter was
placed through femoral vein catheterization. A Tracker-18
microcatheter was advanced into SSS through the angiographic catheter. The patient received a bolus of urokinase (250,000
units) into the SSS followed by continuous infusion at 60,000
units per hour for 41 hours. A repeat angiogram showed
recanalization of SSS. She required blood transfusion due to
falling haematocrit. She was discharged home on warfarin with
a normal neurologic exam but still had papilloedema.
Patient 3: A 3-½ week old boy who had prolonged hypoglycaemia at birth was admitted with lethargy and poor oral
intake. Initial neurologic examination was unremarkable
except for lethargy. The hospital course was complicated by
sepsis, acute renal failure, disseminated intravascular coagulation (DIC), myocarditis and seizures. Head CT scan
showed a right frontal intraparenchymal haemorrhage.
Cerebral angiography showed thrombosis of the Superior
Sagittal Sinus, Transverse Sinus, Sigmoid sinus, and internal
jugular vein. A Tracker-18 catheter was advanced into SSS
through transfemoral angiographic catheter. He received a
bolus of urokinase (30,000 units) into the SSS followed by
local TPA infusion at 0.5 mg/kg/hour. Recanalization was
not achieved. The patient died six hours after TPA infusion.
An autopsy showed cardiomyopathy, extensive dural venous
sinus thrombosis and pulmonary artery thrombosis, without
evidence of haemorrhagic complications.

Discussion
A growing body of evidence suggests that local
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urokinase thrombolysis is relatively safe and effective in adult patients with cerebral venous thrombosis
(CVT). Horowitz et al.3 reported 13 patients including a 12year-old boy treated with local urokinase thrombolysis. In a
review of 20 patients with SSST, Wasay et al.4 found local
urokinase thrombolysis to be relatively safe and effective.
Local thrombolysis using recombinant tissue plasminogen
activator (TPA) has been suggested recently as an alternative to urokinase. Kim et al.5 reported nine adult patients
with dural sinus thrombosis treated with local TPA with
excellent outcome. Frey et al.6 summarized 12 adult patients
with cerebral venous thrombosis who were treated with
combined intrathrombus rtPa and intravenous heparin. Nine
patients had significant clinical improvement. Two patients
showed worsening of haemorrhage.
CVT in children causes significant morbidity and
mortality. One literature review found a16% mortality and
22% with long term disability in paediatric patients with
CVT. Supportive care without anticoagulation is the mainstay of treatment in most cases characterized by limited
thrombosis.7 A recent study of 22 paediatric patients with
CVT showed intravenous heparin or low molecular weight
heparin (LMWH) to be safe and effective.2 The experience
with thrombolytic therapy in paediatric CVT is limited to a
few case reports.8-10 Griesmer et al8 reported a 10-year-old
boy with SSST, TST, StS and sigmiod sinus thrombosis.
Due to progressive neurological deterioration he was treated with local Urokinase thrombolysis with dramatic
improvement. Wong et al.9 reported a one-day-old neonate
with parasagittal haemorrhage due to cortical vein thrombosis. The patient recovered completely after local urokinase
thrombolysis. Gebara et al.10 reported a nine-week old girl
with dural sinus thrombosis secondary to subclavian vein
catheterization. She had complete recovery after local
urokinase thrombolysis.
Anticoagulation is commonly used for adult patients
with SSST; however anticoagulation may not ensure neurologic recovery. There is a growing interest in the use of local
thrombolysis with urokinase or TPA for CVT. More than 90
adult cases of CVT treated with local thrombolysis have
been reported in literature.4 Because of important maturational differences in cerebrovascular and coagulational systems of infants and children compared with adults, therapies
that had been proven to be safe and effective in adult
patients may not be directly extrapolated to the paediatric
age group.
One of our children had nephrotic syndrome and another had lupus nephritis. A hypercoaguable state in nephrotic
syndrome is probably related to functional anti-thrombin III
deficiency. Because mechanism of heparin is based on antithrombin III activity, its effects are variable in patients with
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nephrotic syndrome. Due to extensive thrombosis and comorbidity, local thrombolytic therapy was chosen.
Collagen vascular disease is a well-known risk factor for CVT. Local thrombolytic therapy has been used previously in adult patients with SLE. Despite the presence of
small SDH, thrombolysis was used in the second patient
because of progressive neurological deterioration despite
heparinization. Her symptoms improved after local thrombolysis.
The third patient had extensive comorbidity and
thromboses of multiple dural sinuses. When patency of SSS
was not achieved with urokinase bolus he was switched to
tPa infusion. His death was unrelated to either his dural
sinus thrombosis or to the thrombolytic therapy but it was
due to his overwhelming systemic illness. No new intracranial haemorrhage or worsening of frontal haematoma was
identified on autopsy.
Our study shows the safety of local urokinase thrombolysis in three children with CVT despite the presence of
preexisting intracranial haemorrhages in two patients. The
thrombolysis led to recanalization and neurologic recovery
in two cases. The poor outcome in the third patient was
most likely due to the underlying systemic illness. Local
thrombolysis appears to be reasonably safe in children with
CVT and deteriorating neurologic status. However, firm
conclusions should await further experience and prospective randomized trials.
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